The Chemours Company (NYSE:CC) finished Friday with a subtraction of -$0.26 to close at $30.62, a downside of -0.84 percent. An average of 724,780 shares of common stock have been traded in the last five days. There was a gain of $0.99 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 1,178,320 shares traded, while the 50-day average volume stands at 1,296,264.
CC stock has decreased by -1.38% in the last month. The company shares reached their 1-month lowest point of $29.08 on 12/22/22. With the stock rallying to its 52-week high on 06/06/22, shares of the company touched a low of $22.56 and a high of $44.95 in 52 weeks. It has reached a new high 16 times so far this year and lost -8.76% or -$2.94 in price. In spite of this, the price is down -31.88% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
CC stock investors should be aware that The Chemours Company (CC) stock had its last reported insider trading activity 207 days ago on Jun 07. In this transaction, the insider spent $965,170. SVP, CFO, Ralhan Sameer, disposed of 20,175 shares at a price of $40.01 on May 09. The insider now owns more than $807,202 worth of shares. Prior to that, SVP, CFO Ralhan Sameer went on to Sale 35,188 shares at $40.14 each on May 06. An amount of $1,412,446 was transacted.
The Chemours Company (CC) has a trailing price-to-earnings (P/E) ratio of 5.46. The stock’s beta is 1.85. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.63, the price-to-book (PB) ratio at 3.71, and the price-to-cash flow ratio at 13.61.
The company has a payout ratio of 17.50%. The company’s most recent quarterly dividend payment was $0.25 a share, without any change from last year. Its latest increase dividend $0.08 reported on Friday August 3 2018.
The quick ratio of The Chemours Company for the three months ended September 29 was 1.10, and the current ratio was 1.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.73 and a total debt to equity ratio of 2.75 for the quarter ending September 29. Its gross profit as reported stood at $1.38 billion compared to revenue of $6.34 billion.
For the three-month period that ended September 29, The Chemours Company had $3.51 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $240.0 million in the quarter, while revenues were grew 10.83%. The analyst consensus anticipated The Chemours Company’s latest quarter earnings to come in at $1.04 per share, but it turned out to be $1.24, a 19.20% surprise. For the quarter, EBITDA amounted to $335.0 million. Shareholders own equity worth $150.92 million.
From a technical analysis perspective, let’s take a brief look at The Chemours Company (CC) price momentum. RSI 9-day as of the close on 30 December was 49.25%, suggesting the stock is Neutral, with historical volatility in this time frame at 40.64%.
As of today, CC’s price is $30.64 +3.34% or $0.99 from its 5-day moving average. CC is currently trading -2.02% lower than its 20-day SMA and -11.09% lower than its 100-day SMA. However, the stock’s current price level is +6.43% above the SMA50 and +6.17% above the SMA200.
The stochastic %K and %D were 44.24% and 45.93%, respectively, and the average true range (ATR) was 1.07. With the 14-day stochastic at 47.98% and the average true range at 1.12, the RSI (14) stands at 49.29%. The stock has reached -0.05 on the 9-day MACD Oscillator while the 14-day reading was at -0.20.
Credit Suisse launched coverage on The Chemours Company (NYSE: CC) in its analyst report released on November 01, 2022. The firm assigned the stock an Underperform rating. The consensus rating for The Chemours Company (CC) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell CC, while 9 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 3 others rate it as a “buy”.
What is CC’s price target for the next 12 months?
Analysts predict a range of price targets between $24.00 and $55.00, with a median target of $33.50. Taking a look at these predictions, the average price target given by analysts for The Chemours Company (CC) stock is $35.00.